Authors:
Dautzenberg, FM
Wichmann, J
Higelin, J
Py-Lang, G
Kratzeisen, C
Malherbe, P
Kilpatrick, GJ
Jenck, F
Citation: Fm. Dautzenberg et al., Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: Rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo, J PHARM EXP, 298(2), 2001, pp. 812-819
Authors:
Dautzenberg, FM
Huber, G
Higelin, J
Py-Lang, G
Kilpatrick, GJ
Citation: Fm. Dautzenberg et al., Evidence for the abundant expression of arginine 185 containing human CRF2alpha receptors and the role of position 185 for receptor-ligand selectivity, NEUROPHARM, 39(8), 2000, pp. 1368-1376
Authors:
Ardati, A
Goetschy, V
Gottowick, J
Henriot, S
Valdenaire, O
Deuschle, U
Kilpatrick, GJ
Citation: A. Ardati et al., Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay, NEUROPHARM, 38(3), 1999, pp. 441-448
Authors:
Dautzenberg, FM
Kilpatrick, GJ
Wille, S
Hauger, RL
Citation: Fm. Dautzenberg et al., The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: Generation of chimeric receptors with a novel ligand-selective profile, J NEUROCHEM, 73(2), 1999, pp. 821-829
Authors:
Henriot, S
Dautzenberg, FM
Kilpatrick, GJ
Citation: S. Henriot et al., Urocortin: slower dissociation than corticotropin releasing factor from the CRF binding protein, EUR J PHARM, 376(3), 1999, pp. 321-324